MDT

Medtronic

Fundamental data last updated:March 30, 2026

company profile

SECTOR

Healthcare

industry

Medical Devices

Exchange

NYSE

County of HQ

United States

Next Earnings Date

05/20/26

Business Summary

Medtronic is a global medical device company that develops and manufactures products used in the treatment of cardiovascular, neurological, surgical, and other chronic conditions. The company provides medical technologies, services, and solutions to hospitals, physicians, and healthcare systems worldwide.

VALUATION

P/E

24.3

Market Cap ($M USD)

$111,877

Forward P/E

14.3

PEG

2.7

PRICE TO SALES

3.2

PRICE TO BOOK

2.3

EV / EBITDA

14.1

5-Year Average P/E

DIVIDEND

Yield

3.30%

Annual Payout

$2.84

Payout Ratio

78.60%

Consecutive Years of Dividend Growth

10+

5-Year Dividend Growth Rate

4.10%

Financial Health & Profitability

Earnings Per Share

$3.60

Next Year EPS Growth Estimate

$6.09

Next Year Revenue Growth Estimate

6.40%

Return on Equity (ROE)

9.40%

Operating Margin

18.60%

Debt-to-Equity

0.6

Piotroski F-Score

7

Altman Z-Score

2.9

Return on Invested Capital (ROIC)

6.90%%

Current Ratio

2.5

Quick Ratio

Gainseekers Quantitative Analysis

Summary

Medtronic operates in the Healthcare sector within the Medical Devices industry and has a market cap of $111,877 million on the NYSE. The company trades at a P/E of 24.3 and a forward P/E of 14.3, with a PEG Forward of 2.7, while delivering a 6.40% return on equity and a 9.40% operating margin. With Debt/Equity at 18.60%, a TTM yield of 0.6, and 4.10% short interest, investors are watching ahead of its next earnings report on 05/20/26.

AI Exposure / Tech Reliance

As a medical device company, Medtronic’s business model relies on advanced technology and innovation, though its financial profile reflects moderate profitability with a 9.40% operating margin. Its valuation metrics, including a forward P/E of 14.3, suggest expectations for continued operational performance rather than high-growth tech expansion.

The Bull Case

The company’s forward P/E of 14.3 compared to a current P/E of 24.3 may indicate anticipated earnings improvement, supported by EPS Next Year estimates of $3.60. Low short interest at 4.10% and institutional ownership of $110.65 suggest steady investor participation.

The Bear Case

A PEG Forward of 2.7 may signal that growth expectations are modest relative to valuation, while Return on Equity of 6.40% and Operating Margin of 9.40% reflect moderate profitability. Additionally, a TTM yield of 0.6 alongside a payout ratio listed at $2.84 could raise questions about capital allocation efficiency.

Market Sentiment & Smart Money

Short Interest %

1.30%

Analyst Consensus

2

Average Analyst Price Target

$110.65

Institutional Ownership %

88.20%

1-Year Beta

0.47

Insider Buying % (6 Mo)

0.30%%

Distance to 52-Week High

82.00%%

Distance to 52-Week Low

109.50%%